{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-000510","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2021-07-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.186431+00:00","generated_at":"2026-06-30T02:55:09.823406+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kodiak Sciences avoids $125M royalty-draw; reduces royalty cap to $450M","bullets":["Company and BBA agreed not to fund second $125M tranche of royalty financing agreement.","Royalty cap reduced from $1,012.5M to $450M (4.5x the $100M already funded).","Decision driven by strong balance sheet after $612M capital raise in Nov 2020 and clinical progress.","Independent board committee ratified the decision."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-000510","json":"https://secwatch.observer/filing/0000950170-21-000510.json","markdown":"https://secwatch.observer/filing/0000950170-21-000510.md","text":"https://secwatch.observer/filing/0000950170-21-000510.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017021000510/0000950170-21-000510-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017021000510/kod-20210721.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T02:55:09.823406+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}